AeRang Kim Archives

Pioneering NF innovation and treatment: Q&A with Benjamin Siegel, MD

April 16, 2025

For more than four decades, Children’s National Hospital has been at the forefront of neurofibromatosis (NF) care, research and treatment. In 2007, Dan and Jennifer Gilbert furthered this mission by establishing the Gilbert Family Neurofibromatosis Institute in honor of their son Nick. The Gilberts have dedicated themselves to eradicating NF and improving the future for those affected. Their partnership with Children’s National has transformed the Institute into a global hub for NF care and innovation.

“Since 1982, we’ve combined compassionate care with cutting-edge innovation to provide the best outcomes for our patients while advancing NF treatment,” says Roger J. Packer, MD, director of the institute.

Dr. Packer leads a team of NF experts, including Benjamin Siegel, MD, clinical co-director of the institute, whose expertise in pediatric neurology and neuro-oncology is critical to the program’s success. In this Q&A, Dr. Siegel shares what sets Children’s National apart, how it benefits patients and the latest NF research advancements.

What makes the Gilbert Family Neurofibromatosis Institute at Children’s National unique from other programs in the country?

The Gilbert Family Neurofibromatosis Institute is the longest-running NF program in the United States, with over 40 years of leadership in advancing the field. We helped establish the initial diagnostic criteria in the 1980s and have been pivotal in chairing the Neurofibromatosis Clinical Trials Consortium. Our involvement in groundbreaking clinical trials led to FDA approval of the first targeted therapies for NF1-associated plexiform neurofibromas. Building upon this strong legacy, we continue to advance the future of care for those affected by NF.

Our multidisciplinary team, led by Sinan Turnacioglu, MD, and myself under Dr. Packer’s direction, integrates diverse expertise. My background in neurology and neuro-oncology, combined with Dr. Turnacioglu’s expertise in neurodevelopmental disabilities, allows us to provide comprehensive, high-quality care. With access to specialized clinical resources, we ensure each patient receives the most informed and well-rounded treatment.

How does the work in this program benefit patients?

Our program’s success lies in its comprehensive, interdisciplinary approach to patient care. NF and schwannomatosis can impact every organ system in the body, making close collaboration among specialists essential to address each patient’s unique needs. Our goal is to act as a “medical home” for individuals with NF, ensuring seamless, coordinated care across neurology, oncology, genetics, orthopedics, neurosurgery, plastic surgery, otolaryngology, endocrinology, cardiology and psychiatry.

Recent expansions include neuropsychology, led by Karin Walsh, PsyD, providing comprehensive clinical neuropsychological testing, and physical medicine and rehabilitation, where Mi Ran Shin, MD, MPH, helps manage musculoskeletal issues and chronic pain. This integrated approach allows us to address the complex concerns of NF patients effectively, improving both their physical function and quality of life.

How is Children’s National leading the way in NF research?

Children’s National is at the forefront of NF research, with groundbreaking translational studies spearheaded by its cutting-edge hospital laboratories. Our team is pioneering the use of organoid models to better understand malignant transformations in NF1-associated low-grade gliomas. With a focus on developing targeted therapies for currently untreatable high-grade gliomas, Children’s National has been selected as a key member of the newly funded Gilbert Family NF1-Assosiated Glioma Consortium, an initiative dedicated to advancing treatment options for NF1-associated gliomas.

As a founding member of the Neurofibromatosis Clinical Trials Consortium (NFCTC), we led pivotal clinical trials on targeted therapies for NF1 and schwannomatosis (NF2) tumors. In 2025, the consortium will launch three new trials focused on NF1-associated plexiform neurofibromas. In development are trials evaluating bone health in NF1, attention deficit disorder in NF1, preventative therapy for NF2-associated schwannomas and new treatments for high-grade gliomas and malignant peripheral nerve sheath tumors (MPNST).

Beyond the NFCTC, Children’s National is a member of the Pediatric Brain Tumor Consortium, contributing to selumetinib research for NF1 gliomas. Additionally, through the leadership of internationally known solid tumor oncologist AeRang Kim, MD, PhD, we’re involved with the Sarcoma Alliance for Research through Collaboration, with a focus on developing treatments for MPNST.

Dr. Walsh’s neuropsychology program has advanced understanding of NF1-related cognitive challenges through studies on MEK inhibitors’ effects on neurocognition and links between sleep disorders and ADHD. It also recently completed a pilot study on the Unstuck and On Target program to improve executive function in NF1.

What else is important for peers to know?

A diagnosis of NF or schwannomatosis can be overwhelming and frightening for families due to the wide range of symptoms and manifestations. This uncertainty can often lead to significant anxiety, as patients and their families may struggle to understand what to expect in terms of medical care, progression and treatment options.

At the Gilbert Family Neurofibromatosis Institute, we aim to ease this uncertainty by providing a comprehensive care approach. We offer not only cutting-edge clinical treatments but also support and guidance through the complexities of the disorder. Our team is committed to addressing concerns, providing updated information about the latest research and connecting families to ongoing clinical trials and support resources. By offering a personalized, multi-disciplinary approach, we help our patients navigate their diagnosis with greater confidence and hope for the future.

Looking ahead, Children’s National is set to advance NF research and care with a five-year grant from the Gilbert Family Foundation. The hospital will collaborate with global institutions to address NF-1 associated transformed gliomas and launch the first clinical study using molecular targeted therapy and immunotherapy to treat this aggressive tumor, marking a key milestone in its commitment to innovative treatments and improved outcomes for children with NF.

Drs. Wessel, Dome and Kim with Michelle Riley-Brown and the Speights

Honor bestowed on AeRang Kim, M.D., Ph.D.

November 4, 2024

On November 1, Children’s National Hospital installed AeRang Kim, M.D., Ph.D., as the first holder of The Lexi Speight Chair in Pediatric Oncology.

Dr. Kim is clinical research director for the Oncology Division within the Cancer and Blood Disorders Center at Children’s National. She is a tenured professor of pediatrics at the George Washington University School of Medicine and Health Sciences.

The big picture

Dr. Kim joins a distinguished group of Children’s National physicians and scientists who hold an endowed chair. Children’s National is grateful to generous donors who altogether have funded 49 professorships.

Professorships support groundbreaking work on behalf of children and their families and foster new discoveries and innovations in pediatric medicine. These appointments carry prestige and honor that reflect the recipient’s achievements and donor’s commitment to advancing and sustaining knowledge.

Why it matters

Since arriving at Children’s National in 2010, Dr. Kim has played a pivotal role in our solid tumor program. She leads the renowned multi-disciplinary Sarcoma Clinic, which includes a comprehensive team of oncologists, nurses, orthopedic surgeons, radiologists, a genetic counselor and a physical therapist. It is one of the few of its kind in the country. Dr. Kim’s dedication and leadership have been instrumental in earning Children’s National recognition as a Sarcoma Alliance Center of Excellence.

Dr. Kim leads clinical trials evaluating new pediatric solid tumor treatments across multiple institutions. She pioneers precision approaches using targeted drugs, advanced devices and cell therapies. Her innovative work attracts numerous grants, including a recent $1.3 million from the Department of Defense.

“The future of cancer treatment is in precision medicine,” says Dr. Kim. “As The Lexi Speight Chair of Pediatric Oncology, I will explore new ways to design clinical trials to accelerate development of new therapies for solid tumors. This could change the paradigm for pediatric cancer treatment.”

Moving the field forward

The Speight family, through their vision and generosity, are ensuring that Dr. Kim and future holders of this chair will launch bold, new initiatives to rapidly advance the field of pediatric oncology, elevate our leadership and improve the lifetimes of children with solid tumors.

“When Lexi died, we had a decision to make about how to channel our grief,” Cyndi Speight, Lexi’s mom, remembered. “And do what we could to help other children and families from experiencing what we did.” And so, Cyndi, her husband Petr, and their daughter Sam established The Lexi Speight Chair in Pediatric Oncology with support from community partners in loving memory of Lexi. The Speight family started Laps for Lexi, an annual 5K run/walk that raised money for both pediatric cancer at Children’s National and a scholarship at Sandy Spring Friends School. This successful event ran for 13 years, bringing hope to children and families. The Speight family’s dedication and passion for advancing solid tumor care ensures that Lexi’s legacy lives on in our pursuit of better treatments for children.

DOD $1.3M award will launch clinical trial to treat sarcoma

March 28, 2023

MPNST is a type of cancer called a sarcoma.

The Department of Defense (DOD) awarded Children’s National Hospital $1.3M to launch a unique clinical trial. The trial will evaluate the safety of a novel drug for patients with a rare but aggressive cancer known as malignant peripheral nerve sheath tumors (MPNST).

MPNST is a type of cancer called a sarcoma. While rare in the general population, about half of all MPNST are diagnosed in people with Neurofibromatosis Type 1 (NF1), a condition characterized by changes in skin coloring.

“MPNST is a life-threatening cancer for which there are no adequate medical options,” said AeRang Kim, M.D., Ph.D., director of clinical research of the Division of Oncology at Children’s National. “With the support of this grant, we will conduct a clinical trial to identify effective agents that could be of great benefit to all patients with NF1 who are at risk for sarcoma.”

MPNST are aggressive and frequently metastasize. The tumors that are not able to be removed with surgery rapidly progress and become lethal. In people with NF1, MPNST often develops within benign tumors, especially atypical benign tumors.

The hold-up in the field

Scientists have been looking at the cell signaling process within both pre-cancerous tumors and cancerous MPNST. Previous research has shown that the MEK and MDM2 signaling pathway influence the development and growth of these tumors. By blocking this interplay, the Zhu Laboratory at Children’s National has demonstrated that tumors can get smaller when treated with drugs that inhibit MEK and MDM2 in pre-clinical models.

What’s unique

The trial is uniquely designed to evaluate target inhibition of novel drugs by looking at signals that may help in determining tumor response. This work will provide people with NF1 and MPNST potentially helpful treatments and increase the knowledge for all people with NF1 and those at risk of MPNST. The drugs will be available to all patients who enroll to the study.

Using high-intensity focused ultrasound to treat solid tumors

February 24, 2023

“I think high-intensity focused ultrasound is a really exciting technology that will allow for a different paradigm of how we think about treating solid tumors, both in a local and in a systemic way,” says AeRang Kim, M.D., oncologist at Children’s National Hospital. Dr. Kim explains high-intensity focused ultrasound (HIFU) and how she and her team have used this technology to treat pediatric solid tumors.

HIFU is energy that can be focused on any region of the body. It allows doctors to provide different types of energy in varying amounts, and it’s typically coupled with magnetic resonance imaging, which allows for precise, focused energy to specific areas with accuracy and temperature guidance.

Children’s National was one of the first pediatric centers to open a clinical trial for the treatment of pediatric solid tumors. Since then, we’ve opened several other clinical trials and combined them with targeted chemotherapy for the ablation of benign tumors and malignant solid tumors. We are one of the few institutions that have this study open and we are leading the clinical trials and coordinating them with other institutions across the country.

Catherine Bollard, M.D., M.B.Ch.B., selected to lead global Cancer Grand Challenges team

June 16, 2022

Cancer Grand Challenges NexTGen team members (left to right): Amy Hont, M.D., AeRang Kim, M.D., Nitin Agrawal, Ph.D., Catherine Bollard, M.D., M.B.Ch.B., Conrad Russell Cruz, M.D., Ph.D., Patrick Hanley, Ph.D., and Anqing Zhang.

A world-class team of researchers co-led by Catherine Bollard, M.D., M.B.Ch.B., director of the Center for Cancer and Immunology Research at Children’s National Hospital, has been selected to receive a $25m Cancer Grand Challenges award to tackle solid tumors in children. Cancer Grand Challenges is a global funding platform, co-founded by Cancer Research UK and the National Cancer Institute in the U.S., that supports a community of diverse, global teams to come together, think differently and take on some of cancer’s toughest challenges.

The Cancer Grand Challenges NexTGen team, co-led by University College London’s Martin Pule, M.D., will be working to develop next-generation cell therapies for children with solid cancers. Cancer is a leading cause of death by disease in children worldwide. Although survival has increased for some pediatric cancers, such as blood cancers, survival for some solid tumors has seen little improvement for more than 30 years. The team hopes to build a much deeper understanding of childhood cancers and develop and optimize novel therapies for children with solid tumors, ultimately hoping to improve survival and diminish the lifelong toxicities often experienced by survivors.

“With our Cancer Grand Challenge, we hope to bring next-generation CAR T-cell therapies to children with solid tumors,” said Dr. Bollard. “What excites me most is the energized, passionate group of people we’ve brought together to take this challenge on. Big problems remain to be addressed, but we believe they can be solved, and that we’re the team to solve them.”

“NexTGen represents crucial and overdue work. It has hope written all over,” said Sara Wakeling, patient advocate on the team and CEO and co-founder of Alice’s Arc, a children’s charity for rhabdomyosarcoma. “NexTGen hopes to transform the way these aggressive solid tumors are treated with less toxic side-effects, giving the children a real chance at growing up and realizing their potential. I’m so proud to be part of this exceptional team of scientists, clinicians and advocates who want to change the story for those diagnosed.”

The NexTGen team unites scientists and clinicians with expertise in immunology, proteomics, mathematics and more, across eight institutions throughout the U.S., U.K. and France. The Children’s National investigators that will also join are:

Nitin Agrawal, Ph.D., associate professor in the Center for Cancer and Immunology Research at Children’s National.
Conrad Russell Cruz, M.D., Ph.D.,principal investigator for the Program for Cell Enhancement and Technologies for Immunotherapies at Children’s National.
Patrick Hanley, Ph.D., chief and director of the cellular therapy program at Children’s National and leader of the Good Manufacturing Practices laboratory.
Amy Hont, M.D., oncologist in the Center for Cancer and Immunology Research at Children’s National.
AeRang Kim, M.D., oncologist in The Center for Cancer and Blood Disorders at Children’s National.
Holly Meany, M.D., oncologist in The Center for Cancer and Blood Disorders at Children’s National.
Anqing Zhang, biostatistician in the Biostatistics and Study Methodology Department at Children’s National.

The team, co-funded by Cancer Research UK, the National Cancer Institute and The Mark Foundation for Cancer Research, aims to bring much needed new treatments to children with solid cancers.

The NexTGen team is one of four new teams announced today as part of Cancer Grand Challenges, representing a total investment of $100m to diverse, global teams to take on some of the toughest challenges in cancer research.

“Cancer is a global issue that needs to be met with global collaboration. This investment in team science encourages diverse thinking to problems that have long hindered research progress,” said David Scott, Ph.D., director of Cancer Grand Challenges, Cancer Research UK. “Cancer Grand Challenges provides the multidisciplinary teams the time, space and funding to foster innovation and a transformative approach. NexTGen is one of four newly funded teams joining a scientific community addressing unmet clinical needs across cancer research.”

Find out more

Cancer Grand Challenges supports a global community of diverse, world-class research teams with awards of £20m/$25m to come together, think differently and take on cancer’s toughest challenges. These are the obstacles that continue to impede progress and no one scientist, institution or country will be able to solve them alone. Cancer Grand Challenges teams are empowered to rise above the traditional boundaries of geography and discipline.

Founded by the two largest funders of cancer research in the world – Cancer Research UK and the National Cancer Institute* in the U.S. – Cancer Grand Challenges aims to make the progress against cancer we urgently need. Cancer Grand Challenges currently supports more than 700 researchers and advocates across 10 countries, representing 11 teams are supported to take on 10 of the toughest challenges in cancer research.

The Cancer Grand Challenges NexTGen team, announced June 16, 2022, is taking on the initiative’s Solid Tumours in Children challenge. It is led by Dr. Bollard (Children’s National) and Dr. Pule (University College London), along with 23 co-investigators and 7 patient advocates, and is spread across eight institutions across the U.S., U.K. and France: Cardiff University; Children’s Hospital of Philadelphia; Children’s National Hospital; INSERM; the Institute of Cancer Research; Stanford Medicine; Stanford University; University College London. The Cancer Grand Challenges NexTGen team is funded by Cancer Research UK, the National Cancer Institute in the U.S. and The Mark Foundation for Cancer Research.

*The National Cancer Institute is part of the National Institutes of Health.

Promising new pediatric oncologic applications for focused ultrasound

November 23, 2020

Earlier this month, AeRang Kim, M.D., Ph.D., oncologist at Children’s National Hospital, spoke at the Focused Ultrasound Foundation’s 7th International Symposium on Focused Ultrasound about the latest developments in focused ultrasound applications for pediatric oncology.

Dr. Kim and a team of researchers at Children’s National belong to the IGNITE (image guided non-invasive therapeutic energy) team, a multidisciplinary group working to develop and transform focused ultrasound applications that will minimize treatment side effects and increase efficacy in pediatric cancer care.

In 2015, the IGNITE team conducted its first trial with a study of MR-guided high-intensity focused ultrasound (MR-HIFU) for treating painful osteoid osteomas (a benign bone tumor) in children. This was followed by a trial of MR-HIFU ablation for pediatric solid tumors.

“MR-HIFU has a potential role in local treatment of tumors, both benign and malignant,” Dr. Kim said. “What I’m most excited about is that MR-HIFU has the flexibility to be combined with other treatments such as heat sensitive targeted therapy and immune therapy. I believe this combination approach will have the highest impact in terms of safety and efficacy in pediatric cancer care.”

“MR-HIFU has a potential role in local treatment of tumors, both benign and malignant,” says AeRang Kim, M.D., Ph.D. “What I’m most excited about is that MR-HIFU has the flexibility to be combined with other treatments such as heat sensitive targeted therapy and immune therapy.”

Focused ultrasound is an emergent, non-invasive therapeutic technology that uses ultrasonic energy to target tissue deep in the body without incisions or radiation, thus resulting in minimal discomfort and few complications. This also allows for rapid patient recovery. The applications are wide-ranging: from thermal ablation of tumors and other lesions to blood-brain barrier opening, to increasing tumor vasculature for improved drug delivery, to augmenting immune response, among many others.

The team is now working on combinations of focused ultrasound with other therapies, such as chemotherapy. On the third clinical trial open for accrual at Children’s National, they combine MR-HIFU with lysothermosensitive liposomal doxorubicin, a heat-activated form of the cancer drug doxorubicin, to treat pediatric solid tumors. Although results are still preliminary, the hope is that the technology will mitigate some of the acute and late effects of current multimodal therapy in children. “We want to provide more efficacy and precision with these therapies,” said Dr. Kim.

In reflecting on the potential of this new approach, Dr. Kim believes the findings can help change the way experts think about cancer treatment. The team is studying pre-clinical models of pediatric cancer to evaluate the different modalities of MR-HIFU with immune checkpoint inhibitors. Understanding that there are limitations of MR-HIFU ablation alone, Dr. Kim believes the future for most pediatric cancer applications will be combining approaches using the various bioeffects of focused ultrasound.

“We hope that if promising effects in multiple models utilizing this combination, we can translate these findings into the clinical setting,” she said, noting that the clinical trials led by her team are among the first in the U.S. of HIFU for children. “Children’s National is one of the first pediatrics centers to lead a HIFU program and the Focus Ultrasound Foundation’s first Center of Excellence focused exclusively in pediatrics. We hope to continue to expand our findings and improve pediatric cancer care that’s more precise, less toxic, less invasive and pain free.”

Children’s National designated Center of Excellence by Focused Ultrasound Foundation

September 28, 2020

“This designation provides a high level of recognition and legitimacy to the work our Children’s National team has done with MR-HIFU over many years,” says Karun Sharma, M.D., PhD, director of Interventional Radiology and associate director of clinical translation at the Sheikh Zayed Institute for Pediatric Surgical Innovation.

More precise, less invasive and less painful surgery with lower risk of complications and no radiation exposure – these are some of the benefits of treating pediatric tumors with Magnetic Resonance Guided High Intensity Focused Ultrasound (MR-HIFU). And now the Focused Ultrasound Foundation has designated Children’s National Hospital as the first global pediatric Center of Excellence (COE) for using this technology to help patients with specific types of childhood tumors.

“This designation provides a high level of recognition and legitimacy to the work our Children’s National team has done with MR-HIFU over many years,” says Karun Sharma, M.D., PhD, director of Interventional Radiology and associate director of clinical translation at the Sheikh Zayed Institute for Pediatric Surgical Innovation (SZI) at Children’s National. “This will allow our focused ultrasound program to expand to other areas of interest and become more cohesive while continuing to uncover additional clinical indications for pediatric patients.”

At Children’s National, radiologists use MR-HIFU to focus an ultrasound beam into lesions, usually tumors of the bone and soft tissues, to heat and destroy the tissue in that region. There are no incisions at all. In 2015, Children’s National doctors became the first in the U.S. to use MR-HIFU to treat pediatric osteoid osteoma, a painful, but benign, bone tumor that commonly occurs in children and young adults. The trial, led by Dr. Sharma, demonstrated early success in establishing the safety and feasibility of noninvasive MR-HIFU in children as an alternative to the current, more invasive approaches to treat these tumors. The team also conducted another clinical trial, led by AeRang Kim, M.D., Ph.D., a pediatric oncologist, to treat relapsed soft tissue tumors such as sarcomas.

Since then, the Children’s National team has built an active clinical trials program and become a leader in translation of focused ultrasound for the treatment of pediatric solid tumors. The center is currently investigating the treatment of malignant solid tumors with focused ultrasound alone and combined with chemotherapy.

“Focused ultrasound offers a number of important benefits over traditional therapies, which are especially paramount for the pediatric population,” said Focused Ultrasound Foundation Chairman Neal F. Kassell, M.D. “The team at Children’s National has an exemplary track record in using this technology to pioneer new treatment options for their patients, and we look forward to collaborating and supporting their future research.”

As a designated COE, Children’s National has the necessary infrastructure to support the ongoing use of this technology, especially for carrying out future pediatric clinical trials. This infrastructure includes an ethics committee familiar with focused ultrasound, a robust clinical trials research support team, a data review committee for ongoing safety monitoring and annual safety reviews, and a scientific review committee for protocol evaluation.

The program also features a multidisciplinary team of clinicians and investigators from SZI, radiology, oncology, surgery and orthopedics. With the new designation and continued expansion, we will expand MR-HIFU to other areas such as neuro-oncology, neurosurgery, and urology. Ongoing and future work will investigate a rational combination of MR-HIFU with local tumor drug delivery, immunotherapy and cellular therapy.

“This recognition sets us apart as a premier pediatric institution, and will allow us to pave the way to make pediatric surgery more precise and less invasive,” says Dr. Sharma.

Clinical Trial Spotlight: Searching for effective therapies for malignant peripheral nerve sheath tumors

December 11, 2019

Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft tissue sarcomas and the most common malignancy associated with neurofibromatosis type 1 (NF1).

Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft tissue sarcomas and the most common malignancy associated with neurofibromatosis type 1 (NF1). Half of all MPNST are seen in NF1 patients, and MPNST is a leading cause of mortality in young patients with NF1. Researchers led by AeRang Kim, M.D., Ph.D., a pediatric oncologist at Children’s National Hospital, are now searching for a medical treatment for this rare disease that currently has dismal survival rates.

“Through consortia efforts, we’ve been able to open and accrue in single histology trials of really rare diseases such as MPNST for which there are no known curative therapies other than surgery, and surgery is very difficult or not feasible in many patients,” says Dr. Kim, the principal investigator for the SARC031 trial sponsored by the Sarcoma Alliance for Research through Collaboration. “In this trial in particular, our hope is to find a new therapy that will benefit patients with MPNST for which we have no known effective medical therapies.”

Using a combination of drugs that target specific pathways involved in MPNST growth, Dr. Kim and colleagues at four other institutions offering the SARC031 trial will monitor patients to see if the drugs shrink, slow down or stop the growth of MPNSTs. Based on preclinical data demonstrating substantial MPNST shrinkage in mice treated with a combination of MEK and mTOR inhibitors, SARC031 is a trial of the MEK inhibitor selumetinib in combination with the mTOR inhibitor sirolimus for patients with unresectable or metastatic MPNST. The primary objective is to determine the clinical benefit of the combination.

SARC031: A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors

PI: AeRang Kim, M.D., Ph.D.
Title: SARC031: A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
Status: Recruiting

For more information about this trial, contact:

AeRang Kim, M.D., Ph.D.
202-476-2800
AeKim@childrensnational.org

Click here to view Open Phase 1 and 2 Cancer Clinical Trials at Children’s National.

The Children’s National Center for Cancer and Blood Disorders is committed to providing the best care for pediatric patients. Our experts play an active role in innovative clinical trials to advance pediatric cancer care. We offer access to novel trials and therapies, some of which are only available here at Children’s National. With research interests covering nearly aspect of pediatric cancer care, our work is making great advancements in childhood cancer.

Tag Archive for: AeRang Kim